Ir para o conteúdo principal

United StatesÚltimas notícias

Grafa

Agios discontinues tebapivat program in lower-risk myelodysplastic syndromes after Phase 2b trial fails

Agios Pharmaceuticals (NASDAQ:AGIO) announced that it will discontinue the clinical development of its investigational oral therapy tebapivat for lower-risk myelodysplastic syndromes (LR-MDS) after a Phase 2b study failed to meet its predefined threshold for advancement.

Leia mais
Grafa

Merck secures FDA breakthrough status for Calderasib and Keytruda lung cancer combination

Merck (NYSE:MRK) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to its investigational oral drug calderasib when paired with the company’s blockbuster immunotherapy Keytruda, accelerating its development path for newly diagnosed lung cancer patients.

Leia mais